Guillain-Barré syndrome (GBS) is an acute inflammatory ... determined in serum samples pretreatment and again 2 weeks after treatment. Some patients also had IgG levels measured at 4 weeks ...
The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...
Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...
The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...
Rare Guillain-Barré Syndrome cases were found after ChAdOx1 vaccine in India; vigilance is urged despite vaccine’s overall safety.
Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...
Peruvian authorities Saturday declared a 90-day nationwide sanitary emergency due to the “unusual increase” in cases of Guillain-Barré Syndrome ... for the treatment of patients affected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback